The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Very much looking forward to Tuesdays presentation
..analysts evaluations fit best for well balanced portfolios.
…and to make it clear it’s only up to clinical success at this point. Clinical results do define the success and there is no correlation to analysts evaluations. IMO
…but of course at times like this the root cause is the scarcity of money for many. Still there is an abundance of money for good investment opportunities like we can see in some hot shares how the sp skyrocket. Hopefully someday any day soon here as well.
Someday we know if the sp drop happened due to a gullible trust, unfortunate mistake or because of a manipulative action. I am not that imaginative that I could guess who all could be benefiting now. With lower sp it’s possible to spread the ownership wider. Would be also interesting to know who are the investors in that particular IPF fund committed to Faron?
Thanks Sax. I’m gutted our value halved but I appreciate that was temporary. We just need to some great data now and we will get past 200 quickly
Well done for keeping the faith Santhi . No more scares from now on.
There's always a little bit of fear when you don't know exactly whats going on , but after the other days presentation , I'm even more optimistic and excited for the coming years .
Thanks guys. I did one last top yesterday to bring my average down a little…. 🙏
Other results also due by end March
The company get the data tomorrow and relay on Tuesday.
Tuesday latest I would say ;)
Are we definitely getting some data tomorrow then?
Data coming in tomorrow, they are processing over the weekend for Tuesday webcast. Might be some indication with trades on Monday..
I like their approach. Firstly the unfortunate hick-up solved and now apparently positive clinical information landing. Financing will be arranged in a way or an other way combining various vehicles like convertible loan, loan, issue and maybe by means of business development agreements. Rather interesting period ahead of us before the AGM. The AGM invitation landed rapidly after the yesterday’s information session on time three weeks and two days before the AGM thus confirmed the current status of matters. It will be glorious days ahead of us if the clinical results continue to be good. IMO
The data is amazing, world class, but my favourite bit of the presentation was when he described the number of companies very keen to get involved. Sufficient for a competitive process. We should see some huge milestone payments included.
I like the sound of 'focus on durability of remission'. This is only going one way now imho
Back over £2 before Tuesday imo
On the Nas site , Faron has been ' on the surveillance list ' since the Feb incident.
As of today , they are off it .
Up 13% over there at 1.84
The market want's reassurance that the business will be able to reach milestones .
The AGM puts that in place .
I was going to wait until after AGM to top up , but had some at £1.33 .
I'm fortunate that I've got cash on the side , and I appreciate others don't , or are deep enough in .
I know its a pain to look at the SP , but my priority now is how many shares I own , not what they are worth today , cos I know in a year or so they won't be £1.33 .
All grand we only lost half our value.
the ipf fiasco was addressed immediately . the ' hiccup' was all it was . markuu takes full responsibility . all sorted , in as much as business as usual - until next fundraise . fair play for at least admitting it was a **** up .
moving on..
the rest of the presentation was very encouraging .
ok they will be needing to fundraise after agm - details to follow ( shareholders given some kind of vote on how they would like it to happen ? )
but i think that we will shortly be seeing some very good data on bexmab prior to the agm ( next week he suggests )
also looking towards a bidding process later in year for bex liscencing /partnerships . there are multiple interested parties .
fast track / breakthrough status applied for in aml/mds
new sites
bexmab data is looking so good that markku doesn't expect much resistance from fda in accelerating bex to market .
they only had 7m shares to play with this side of agm - hence the delay in fundraise .
details of agm should be out soon.
what will the sp be like at the fundraise . hard to say . higher ? lower ? rights issue ?
some good news to sway things . we are at very low level given what is coming .
You can log in here -
https://faron.videosync.fi/q4-2023
Usually you can fire in questions as soon as it starts - and they will quite often answer them if they are straightforward enough .
Great feedback as always Sax… Do you know how I can watch the virtual brief at 12.00 today? Thanks in advance
No new info yet on Bexmab today then . Perhaps they want that on a separate day - get the financials done with , and any awkward questions ( I hope they get some ) - then move on with positives .
The excellent BEXMAB data have intensified numerous ongoing partnering discussions, and we are looking forward to advancing these discussions over the coming year.
None of this work would be possible without the ongoing support from our shareholders, to whom I express my sincere thanks. And to my colleagues on the management team, and the wider Faron community, thank you for your continued commitment to making this Company's vision a reality and bringing the promise of bexmarilimab to patients.
Faron have 'Orphan Drug' Status for Bex . This could accelerate the route to market for AML/MDS.
They plan to apply for BLA in early 2025 .
FDA could recommend a rolling P2/3 study - small numbers - low relative cost - then finally - They start getting income !
That changes the game a bit .
Hopefully the market will see this as a great opportunity .